Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data

benzinga.com/news/health-care/25/06/46123159/pfizer-seeks-label-expansion-for-hemophilia-drug-after-promising-data

Hympavzi cut annualized bleeding rate by 93% vs. on-demand care in hemophilia patients with inhibitors.
- The 12-month Phase 3 BASIS trial reported no deaths or thromboembolic events.
- Get ahead of Wall Street reactions—Benzinga Pro delivers signals, squawk, and news fast. Now 60% off…

This story appeared on benzinga.com, 2025-06-26 17:47:17.
The Entire Business World on a Single Page. Free to Use →